Funding vaccines for emerging infectious diseases.
Identifieur interne : 000A63 ( PubMed/Curation ); précédent : 000A62; suivant : 000A64Funding vaccines for emerging infectious diseases.
Auteurs : Gary Wong [République populaire de Chine] ; Xiangguo Qiu [Canada]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2018.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- Communicable Disease Control, Communicable Diseases (epidemiology), Communicable Diseases, Emerging (prevention & control), Coronavirus Infections (prevention & control), Disease Outbreaks (prevention & control), Epidemics (prevention & control), Global Health (economics), Humans, Vaccination, Vaccines (economics), Zika Virus Infection (prevention & control).
- MESH :
- chemical , economics : Vaccines.
- economics : Global Health.
- epidemiology : Communicable Diseases.
- prevention & control : Communicable Diseases, Emerging, Coronavirus Infections, Disease Outbreaks, Epidemics, Zika Virus Infection.
- Communicable Disease Control, Humans, Vaccination.
Abstract
Immunization has played a large role in substantially reducing the infected and death tolls from infectious diseases. In the case of emerging diseases, the identity of the pathogen responsible, as well as the time and location for the next outbreak, cannot be accurately predicted using current means. Coupled with disjointed efforts towards the development of vaccines and a lack of funds and desire to advance promising products against known emerging pathogens to clinical trials, there has been a shortage of approved products ready for emergency use. Recent outbreaks have exposed these weaknesses, and the Coalition for Epidemic Preparedness Innovations (CEPI) was created in 2016 to address these issues. In this commentary, we discuss the establishment of such a global vaccine fund, and provide some additional points to consider for stimulating further discussion on this comprehensive, ambitious initiative.
DOI: 10.1080/21645515.2017.1412024
PubMed: 29194012
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A63
Links to Exploration step
pubmed:29194012Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Funding vaccines for emerging infectious diseases.</title><author><name sortKey="Wong, Gary" sort="Wong, Gary" uniqKey="Wong G" first="Gary" last="Wong">Gary Wong</name><affiliation wicri:level="1"><nlm:affiliation>a Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital , Shenzhen , China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>a Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital , Shenzhen </wicri:regionArea></affiliation></author><author><name sortKey="Qiu, Xiangguo" sort="Qiu, Xiangguo" uniqKey="Qiu X" first="Xiangguo" last="Qiu">Xiangguo Qiu</name><affiliation wicri:level="1"><nlm:affiliation>b Special Pathogens Program, National Microbiology Laboratory , Winnipeg , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>b Special Pathogens Program, National Microbiology Laboratory , Winnipeg </wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29194012</idno><idno type="pmid">29194012</idno><idno type="doi">10.1080/21645515.2017.1412024</idno><idno type="wicri:Area/PubMed/Corpus">000A63</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A63</idno><idno type="wicri:Area/PubMed/Curation">000A63</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Funding vaccines for emerging infectious diseases.</title><author><name sortKey="Wong, Gary" sort="Wong, Gary" uniqKey="Wong G" first="Gary" last="Wong">Gary Wong</name><affiliation wicri:level="1"><nlm:affiliation>a Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital , Shenzhen , China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>a Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital , Shenzhen </wicri:regionArea></affiliation></author><author><name sortKey="Qiu, Xiangguo" sort="Qiu, Xiangguo" uniqKey="Qiu X" first="Xiangguo" last="Qiu">Xiangguo Qiu</name><affiliation wicri:level="1"><nlm:affiliation>b Special Pathogens Program, National Microbiology Laboratory , Winnipeg , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>b Special Pathogens Program, National Microbiology Laboratory , Winnipeg </wicri:regionArea></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Communicable Disease Control</term><term>Communicable Diseases (epidemiology)</term><term>Communicable Diseases, Emerging (prevention & control)</term><term>Coronavirus Infections (prevention & control)</term><term>Disease Outbreaks (prevention & control)</term><term>Epidemics (prevention & control)</term><term>Global Health (economics)</term><term>Humans</term><term>Vaccination</term><term>Vaccines (economics)</term><term>Zika Virus Infection (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Contrôle des maladies contagieuses</term><term>Flambées de maladies ()</term><term>Humains</term><term>Infection par le virus Zika ()</term><term>Infections à coronavirus ()</term><term>Maladies transmissibles (épidémiologie)</term><term>Maladies transmissibles émergentes ()</term><term>Santé mondiale (économie)</term><term>Vaccination</term><term>Vaccins (économie)</term><term>Épidémies ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Vaccines</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Global Health</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Communicable Diseases</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Communicable Diseases, Emerging</term><term>Coronavirus Infections</term><term>Disease Outbreaks</term><term>Epidemics</term><term>Zika Virus Infection</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Santé mondiale</term><term>Vaccins</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Maladies transmissibles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Communicable Disease Control</term><term>Humans</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Contrôle des maladies contagieuses</term><term>Flambées de maladies</term><term>Humains</term><term>Infection par le virus Zika</term><term>Infections à coronavirus</term><term>Maladies transmissibles émergentes</term><term>Vaccination</term><term>Épidémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immunization has played a large role in substantially reducing the infected and death tolls from infectious diseases. In the case of emerging diseases, the identity of the pathogen responsible, as well as the time and location for the next outbreak, cannot be accurately predicted using current means. Coupled with disjointed efforts towards the development of vaccines and a lack of funds and desire to advance promising products against known emerging pathogens to clinical trials, there has been a shortage of approved products ready for emergency use. Recent outbreaks have exposed these weaknesses, and the Coalition for Epidemic Preparedness Innovations (CEPI) was created in 2016 to address these issues. In this commentary, we discuss the establishment of such a global vaccine fund, and provide some additional points to consider for stimulating further discussion on this comprehensive, ambitious initiative.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29194012</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>07</Month><Day>03</Day></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Funding vaccines for emerging infectious diseases.</ArticleTitle><Pagination><MedlinePgn>1760-1762</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2017.1412024</ELocationID><Abstract><AbstractText>Immunization has played a large role in substantially reducing the infected and death tolls from infectious diseases. In the case of emerging diseases, the identity of the pathogen responsible, as well as the time and location for the next outbreak, cannot be accurately predicted using current means. Coupled with disjointed efforts towards the development of vaccines and a lack of funds and desire to advance promising products against known emerging pathogens to clinical trials, there has been a shortage of approved products ready for emergency use. Recent outbreaks have exposed these weaknesses, and the Coalition for Epidemic Preparedness Innovations (CEPI) was created in 2016 to address these issues. In this commentary, we discuss the establishment of such a global vaccine fund, and provide some additional points to consider for stimulating further discussion on this comprehensive, ambitious initiative.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>a Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital , Shenzhen , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Xiangguo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>b Special Pathogens Program, National Microbiology Laboratory , Winnipeg , Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Department of Medical Microbiology , University of Manitoba , Winnipeg , Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI109762</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IER–143487</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021821" MajorTopicYN="N">Communicable Diseases, Emerging</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058872" MajorTopicYN="N">Epidemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Ebola</Keyword><Keyword MajorTopicYN="Y">MERS</Keyword><Keyword MajorTopicYN="Y">SARS</Keyword><Keyword MajorTopicYN="Y">Zika</Keyword><Keyword MajorTopicYN="Y">funding</Keyword><Keyword MajorTopicYN="Y">influenza</Keyword><Keyword MajorTopicYN="Y">vaccine</Keyword><Keyword MajorTopicYN="Y">vaccinology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29194012</ArticleId><ArticleId IdType="doi">10.1080/21645515.2017.1412024</ArticleId><ArticleId IdType="pmc">PMC6067896</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2010 Dec 16;29(2):304-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21034824</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Aug 7;424(6949):681-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12904795</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Jul;11(7):786-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15937495</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2017 Feb 16;376(7):610-613</Citation><ArticleIdList><ArticleId IdType="pubmed">28099066</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2016 Oct 14;354(6309):213-217</Citation><ArticleIdList><ArticleId IdType="pubmed">27738169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2016 Dec 14;20(6):810-821</Citation><ArticleIdList><ArticleId IdType="pubmed">27916476</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Aug 11;29(35):5846-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21722688</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2015 Jul 23;373(4):297-300</Citation><ArticleIdList><ArticleId IdType="pubmed">26200974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000A63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:29194012
|texte= Funding vaccines for emerging infectious diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29194012" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |